FB 1001
Alternative Names: FB-1001Latest Information Update: 24 Jul 2024
Price :
$50 *
At a glance
- Originator 4B Technologies
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glaucoma
Most Recent Events
- 17 Jul 2024 Shanghai General Hospital plans a phase-I trial for Angle-closure glaucoma and Optic nerve disorders (In adults, In the elderly) in China (Intravitrous, injection) in August 2024 (NCT06506305),
- 05 Oct 2021 4B Technologies plans to submit IND for Glaucoma (4B Technologies pipeline, October 2021)
- 01 Oct 2021 Preclinical trials in Glaucoma in China (unspecified route) (4B Technologies pipeline, October 2021)